Androgen deprivation therapy: Past, present and future

BJU International

Volumn 109, Issue SUPPL. 6, 2012, Pages 1-12

  Schroder F ^a   Crawford, E D ^b   Axcrona, K ^c   Payne, H ^d   Keane, T E ^e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adjuvant hormonal therapy; Androgen deprivation therapy; GnRH antagonists; Neoadjuvant hormonal therapy; Prostate cancer

Indexed keywords

ABARELIX; ANTIANDROGEN; BICALUTAMIDE; DEGARELIX; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN; MITOXANTRONE; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COMPARATIVE EFFECTIVENESS; CONNECTIVE TISSUE DISEASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; GYNECOMASTIA; HOT FLUSH; HUMAN; IMPOTENCE; INJECTION SITE REACTION; INTERMETHOD COMPARISON; LIBIDO DISORDER; LIVER TOXICITY; MASTALGIA; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MUSCULOSKELETAL DISEASE; ORCHIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; THERAPY DELAY; TREATMENT DURATION; URINARY TRACT INFECTION;

ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; MALE; NEOADJUVANT THERAPY; OLIGOPEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84862201613     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11215.x     Document Type: Review

References (83)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
2. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate cancer. Archives of Surgery 1941; 43: 209-23
3. Heidenreich A, Bolla M, Joniau S et al. European Association of Urology. Guidelines on prostate cancer. January 2011. Available from http://www.uroweb. org/gls/pdf/08-Prostate-Cancer.pdf [Accessed: December 2011]
4. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988; 7: 165-70
5. Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579-82
6. Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. A nn Intern Med 2000; 132: 566-77
7. Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001; 58 (Suppl 2A): 5-9
8. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91: 455-461
9. Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol 2007; 51: 306-13
10. Kabir S, Mancuso P, Rashid P et al. Androgen deprivation therapy. Managing side effects. Aust Fam Physician 2008; 37: 641-5
11. Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-8
12. Tombal B, Berges R. Optimal control of testosterone: a clinical case-based approach of modern androgendeprivation therapy. Eur Urol Suppl 2008; 7: 15-21
13. Van Poppel H, Nilsson S Testosterone surge: rationale for gonadotropinreleasing hormone blockers? Urology 2008; 71: 1001-6
14. Lin GW, Yao XD, Zhang SL et al. Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. Asian J Androl 2009; 11: 443-50
15. Crawford ED, Tombal B, Miller K et al. A phase III extension trial with a one-arm crossover from leuprolide to degarelix: comparison of gonadotropinreleasing hormone agonist and antagonist effect on prostate cancer. J Urol 2011; 186: 889-97
16. Payne H, Mason M. Androgen deprivation therapy as adjuvant/ neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 2011; 105: 1628-34
17. Crawford ED. Hormonal therapy in prostate cancer: historical approaches. Rev Urol 2004; 6 (suppl 7): S3-S11
18. Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011-7
19. Tyrrell CJ, Kaisary AV, Iversen P et al. A randomised comparison of ' Casodex ' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-56
20. Prostate Cancer Trialists ' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-8
21. Hussain S, Gunnell D, Donovan J et al. Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int 2008; 101: 547-55.
22. Bolla M, Van Tienhoven G, Warde P et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010; 11: 1066-73
23. Waxman J, Man A, Hendry WF et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res Ed) 1985; 291: 1387-8
24. Thompson IM. Flare associated with LHRH-agonist therapy. Rev Urol 2001; 3 Suppl 3: S10-4
25. Tombal B. The importance of testosterone control in prostate cancer. Eur Urol Suppl 2007; 6: 834-9
26. Morote J, Orsola A, Planas J et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 1290-5
27. Morote J, Planas J, Salvador C, Ravent ó s CX, Catal á n R, Revent ó s J. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2009; 103: 332-5
28. Trachtenberg J, Gittleman M, Steidle C et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002; 167: 1670-4
29. McLeod D, Zinner N, Tomera K et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58: 756-61
30. Selvaggi F, Khoe GSS, Van Cangh P et al. Comparison of abarelix depot (A-D) and goserelin (G) plus bicalutamide (B) in advanced prostate cancer: results of a multicentre, open-label, randomised, phase III study. Eur Urol 2001; 39 (Suppl 5): 78
31. Druglib.com. Plenaxis (abarelix) summary, March 2012. Available at http://www.druglib.com/druginfo/ plenaxis) [accessed March 2012]
32. Mongiat-Artus P, Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother 2004; 5: 2171-9
33. Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol 2006; 2: 677-96
34. Huhtaniemi I, White R, McArdle CA, Persson BE. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab 2009; 20: 43-50
35. Hanninen M, Venner P, North S. A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Can Urol Assoc J 2009; 3: 369-74
36. Tombal B, Miller K, Boccon-Gibod L et al. Additional analysis of the secondary end point of biochemical recurrence rate in a Phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010; 57: 836-42
37. Schr ö der FH, Tombal B, Miller K et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int 2010; 106: 182-7
38. Boccon-Gibod L, van der Meulen E, Persson B-E. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol 2011; 3: 127-40
39. Lein M, Wirth M, Miller K et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. E ur Urol 2007; 52: 1381-7
40. Lorente JA, Morote J, Raventos C et al. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996; 155: 1348-51
41. Robinson D, Sandblom G, Johansson R et al. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. J Urol 2008; 179: 117-22
42. Johansen JS, Brasso K, Iversen P et al. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res 2007; 13: 3244-9
43. Ramankulov A, Lein M, Kristiansen G et al. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007; 67: 330-40
44. Jung K, Lein M, Von Stephan CHK et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004; 111: 783-91
45. Axcrona K, Aaltomaa S, da Silva CM et al. ADT for volume reduction, symptom relief and quality of life improvement in men with prostate cancer: Degarelix versus goserelin plus bicalutamide. BJU Int 2012; Apr 13. doi: 10.1111/j.1464-410X.2012.11107.x. [Epub ahead of print]
46. Schr ö der FH, Kurth K-H, Fossa SD et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organization for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 2009; 55: 14-22
47. Messing EM, Manola J, Yao J et al. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-9
48. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002; 1: CD003506
49. Studer UE, Whelan P, Albrecht W et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006; 24: 1868-76
50. Loblaw DA, Virgo KS, Nam R et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-605
51. Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-83
52. Roach M III, Bae K, Speight J et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008; 26: 585-91
53. Denham JW, Steigler A, Lamb DS et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011; 12: 451-9
54. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90
55. Horwitz EM, Bae K, Hanks GE et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-504
56. Widmark A, Klepp O, Solberg A et al.; Scandinavian Prostate Cancer Group Study 7, Swedish Association for Urology Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-8
57. Warde P, Mason M, Ding K et al; NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104-11
58. Zelefsky MJ, Leibel SA, Burman CM et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994; 29: 755-61
59. Henderson A, Langley SE, Laing RW. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol (R Coll Radiol) 2003; 15: 318-21
60. Pilepich MV, Krall JM, al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616-23
61. Williams S, Buyyounouski M, Kestin L, Duchesne G, Pickles T. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose. I nt J Radiation Oncol Biol Phys 2011; 79: 724-31
62. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-8
63. Hanks GE, Pajak TF, Porter A et al.; Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972-8
64. Dal Pra A, Cury FL, Souhami L. Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review. Curr Oncol 2010; 17: 28-38
65. Laverdi è re J, Nabid A, De Bedoya LD et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 2004; 171: 1137-40
66. D ' Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299: 289-95
67. Jones CU, Hunt D, McGowan DG et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. New Engl J Med 2011; 365: 107-18
68. Bolla M, De Reijke TM, van Tienhoven G et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009 360: 2516-27
69. Crook J, Ludgate C, Malone S et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60: 15-23
70. Alexander A, Crook J, Jones S et al. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3-versus 8-month randomized trial. Int J Radiat Oncol Biol Phys 2010; 76: 23-30
71. Ward JF, Slezak JM, Blute ML et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95: 751-6
72. Hsu CY, Joniau S, Oyen R et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. E ur Urol 2007; 51: 121-8
73. Van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998; 160: 1392-7
74. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009; 35: 9-17
75. Shelley MD, Kumar S, Coles B, Wilt T, Staffurth J, Mason MD. Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treat Rev 2009; 35: 540-6
76. Shipley WU, Hunt D, Lukka HR et al. Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, N0 disease and elevated PSA levels. J Clin Oncol 2011; 29 (Suppl 7): 1
77. Medical Research Council Clinical Trials Unit. RADICALS-Radiotherapy and androgen deprivation in combination after local surgery: a randomised controlled trial in prostate cancer. Available at: http://www.radicals-trial.org/default. aspx [accessed 23 March 2012]
78. Parker C, Sydes MR, Catton C et al.; RADICALS Trial Management Group. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 2007; 99: 1376-9
79. Verhagen PCMS, Schroder FH, Collette L et al. Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? a systematic review. Eur Urol 2010; 58:261-9
80. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-8
81. Liu W, Laitinen S, Khan S et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15:559-65
82. Briganti A, Karnes RJ, Da Pozzo LF et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN + prostate cancer: results of a matched analysis. Eur Urol 2011; 59: 832-40
83. Dorff TB, Flaig TW, Tangen CM et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011; 29: 2040-5